CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy ...

Pipeline programs: Design continues to progress preclinical activities for its myotonic dystrophy type-1 (DM1) program toward the selection of a development candidate later in 2025. In Huntington's ...

The VA is advancing a landmark initiative to explore the deployment of biometric authentication for access control within its ...

Master AI agent creation with this easy guide. Learn how to design scalable, reliable systems that deliver measurable results ...

The initial POC results, presented April 26, 2025 at the Annual ELITE PED-GI Congress, show crofelemer reduced the required total parenteral nutrition (TPN) and/or supplementary intravenous fluids, ...

Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced positive top-line Phase II study results for its novel ...

NASA is planning to push the boundaries of space exploration with its new Nighthawk Mars helicopter, a cutting-edge mission ...

Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research under Botanical GuidanceClick here to access replay of company's April 30, 2025 investor webcast SAN FRAN ...

Attacks on another Commvault vulnerability became known over the weekend. The update to seal it does not seem to be working.

Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine ...

Galfer reveal Floatech, a new floating disc inspired by MotoGP tech, promising better feel, durability, and heat control - ...